Japan
Dec 09, 2011
Dako enters into collaboration with Genentech on the regulatory submissions of Dako’s HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for pertuzumab
Dako, a worldwide provider of cancer diagnostics solutions, has signed an agreement with Genentech, a member of the Roche Group, to collaborate on the regulatory submissions of Dako’s HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for a Genentech investigational drug candidate, pertuzumab, in patients with advanced HER2-positive breast cancer.
Under the terms of the agreement, Dako and Genentech will collaborate on the regulatory submissions for HercepTest™ and HER2 FISH pharmDx™ in the US market to identify cancer patients who may be eligible for pertuzumab.
"We're pleased to provide Genentech access to our leading competencies. I strongly believe collaborating with Genentech on the joint FDA approval for companion diagnostics for pertuzumab will benefit many breast cancer patients in the future," says Lars Holmkvist, CEO of Dako.
The collaboration on the joint submission process for HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for pertuzumab is in line with Dako’s ongoing strategy to combine its strengths with pharmaceutical companies to grow the offering of Dako’s companion diagnostic assays.
Media Contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako covers essentially all of the global anatomic pathology markets. Dako is owned by a private equity fund EQT. www.dako.com